Zydus Wellness net sales up by 62.1% for Q4 & 46.4% for FY 26  

IMT News Desk
IMT News Desk
· 2 min read
Zydus Wellness reports 62.1% YoY net sales growth in Q4 and 46.4% for FY26, with revenues at ₹14,761 million and ₹39,400 million respectively

Zydus Wellness Limited reported a consolidated growth of 62.1% in Net Sales, which stood at Rs. 14,761 million as compared to Rs. 9,106 million in the corresponding period of the previous year. The Company reported annual Net Sales of Rs. 39,400 million, with a y-o-y growth of 46.4% in FY 26. EBITDA for the period stood at Rs 5,097 million with a growth of 34.2% y-o-y, which includes the post-acquisition performance of the newly acquired business. PAT for FY 26 stood at Rs. 1,972 million.

Sugar Free strengthened its leadership in the sugar substitute category with a market share of 96.1%*. The addition of a new variant – Sugar Free D’lite Choco Spread to the domestic portfolio during the quarter. Sugar Free Green delivered its 20th consecutive quarter of double-digit growth.

RiteBite –Max Protein business continued to outperform while maintaining its leadership in protein snacking and improving EBITDA from breakeven at the time of acquisition a year ago to near double-digit margins. New launches included Max Protein Ultimate Protein Boost (Ready-to-Drink), Max Protein Roots Ghee Jaggery Bar, and Korean-flavoured Chips with multiple flavours.

Glucon-D maintained its leadership position with a 58.9%* MAT market share. Glucon-D entered the performance hydration category with the launch of ‘Glucon-D Recharge’ in Liquid and Sachet formats, offering three flavours across the portfolio, targeting active and health-conscious consumers.

Everyuth leads with 48.6%* share in scrubs and 75.5%* in peel-off masks, ranking fifth in the facial cleansing segment with an 8%* share. Everyuth delivered strong double-digit growth in FY26, driven by innovation, distribution expansion, and enhanced consumer experience, with tan removal further strengthening its saliency, supported by the Q4 launch of the tan removal face wash. The prickly heat powder category with Nycil maintained its number one position with a market share of 33.2%*.

Nutralite delivered double-digit growth, supported by a strong six-year CAGR and consistent performance across the portfolio, while maintaining leadership in the fat spread category. Complan maintained its fourth rank, holding a 4%* market share. During the quarter, the Company commenced direct supply of Complan NutriGro under the kids’ segment.

Comfort Click expanded its portfolio with 11 product launches in Weightworld and Animigo, strengthening its presence in high-growth markets. During the quarter, WeightWorld and Maxmedix expanded their channel presence in the UAE market through a leading e-commerce platform.

Sources: *As per MATMarch’26 report of Nielsen & IQVIA

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk